Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
Neurochem Int ; 108: 27-33, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28192150

ABSTRACT

Neuropathic pain is a type of chronic pain caused by nervous system damage and dysfunction. The pathogenesis of chronic pain is complicated, and there are no effective therapies for neuropathic pain. Studies show that the P2X4 receptor expressed in the satellite glial cells (SGCs) of dorsal root ganglia (DRG) is related to neuropathic pain. Artemisinin is a monomeric component extracted from traditional Chinese medicine and has a variety of important pharmacological effects and potential applications. This study observed the effect of artemisinin on neuropathic pain and delineated its possible mechanism. The chronic constriction injury (CCI) rat model was used in this study. The results demonstrated that artemisinin relieved pain behaviors in the CCI rats, inhibited the expression of P2X4 receptor in the DRG, and decreased the ATP-activated currents in HEK293 cells transfected with P2X4 plasmid. Dual-labeling immunofluorescence showed that the coexpression of P2X4 receptor and glial fibrillary acidic protein (GFAP) in the DRG of CCI rats was increased compared to control rats. After CCI rats were treated with artemisinin, the coexpression of P2X4 receptor and GFAP in the DRG was significantly decreased compared to the CCI group. This finding suggested that artemisinin could inhibit the nociceptive transmission mediated by P2X4 receptor in the DRG SGCs and thus relieve pain behaviors in the CCI rats.


Subject(s)
Artemisinins/therapeutic use , Ganglia, Spinal/metabolism , Neuralgia/drug therapy , Neuralgia/metabolism , Pain Measurement/methods , Receptors, Purinergic P2X4/physiology , Animals , Artemisinins/pharmacology , Dose-Response Relationship, Drug , Ganglia, Spinal/drug effects , HEK293 Cells , Humans , Male , Pain Measurement/drug effects , Purinergic P2X Receptor Antagonists/pharmacology , Purinergic P2X Receptor Antagonists/therapeutic use , Rats , Rats, Sprague-Dawley , Treatment Outcome
3.
Purinergic Signal ; 12(3): 479-87, 2016 09.
Article in English | MEDLINE | ID: mdl-27100355

ABSTRACT

Adenosine triphosphate (ATP) participates in signal transmission by acting on P2X receptors, and the P2X7 receptor is involved in the pathophysiological changes of ischemic injury. The PC12 cell line is a popular model system to study sympathetic neuronal function. Long noncoding RNAs (lncRNAs) are highly expressed in the nervous system and serve as regulatory RNAs. In this study, the effects of NONRATT021972 lncRNA siRNA on P2X7-mediated PC12 neuronal injury after exposure to oxygen-glucose deprivation (OGD) were investigated. Our results showed that the viability of PC12 cells cultured with OGD or the P2X7 agonist BzATP was significantly decreased. Treatment with NONRATT021972 siRNA reversed the decreased viability of PC12 cells under OGD conditions. The upregulated P2X7 mRNA and protein levels in PC12 cells under OGD conditions or BzATP treatment were significantly decreased when pretreated with NONRATT021972 siRNA. Moreover, NONRATT021972 siRNA treatment effectively suppressed the increase in [Ca(2+)]i induced by OGD or P2X7 agonists (ATP or BzATP) in PC12 cells. Therefore, treatment with NONRATT021972 siRNA may decrease sympathetic neuronal injury induced by ischemia.


Subject(s)
Ischemia/metabolism , RNA, Long Noncoding/metabolism , Receptors, Purinergic P2X7/metabolism , Animals , Blotting, Western , Cell Hypoxia , Cell Survival/drug effects , Disease Models, Animal , Gene Knockdown Techniques , Glucose/deficiency , Oxygen , PC12 Cells , Polymerase Chain Reaction , RNA, Long Noncoding/pharmacokinetics , Rats
4.
Purinergic Signal ; 12(1): 127-37, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26630943

ABSTRACT

Adenosine triphosphate (ATP) acts on P2X receptors to initiate signal transmission. P2X7 receptors play a role in the pathophysiological process of myocardial ischemic injury. Long noncoding RNAs (lncRNAs) participate in numerous biological functions independent of protein translation. LncRNAs are implicated in nervous system diseases. This study investigated the effects of NONRATT021972 small interference RNA (siRNA) on the pathophysiologic processes mediated by P2X7 receptors in stellate ganglia (SG) after myocardial ischemic injury. Our results demonstrated that the expression of NONRATT021972 in SG was significantly higher in the myocardial ischemic (MI) group than in the control group. Treatment of MI rats with NONRATT021972 siRNA, the P2X7 antagonist brilliant blue G (BBG), or P2X7 siRNA improved the histology of injured ischemic cardiac tissues and decreased the elevated concentrations of serum myocardial enzymes, creatine kinase (CK), CK isoform MB (CK-MB), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) compared to the MI rats. NONRATT021972 siRNA, BBG, or P2X7 siRNA treatment in MI rats decreased the expression levels of P2X7 immunoreactivity, P2X7 messenger RNA (mRNA), and P2X7 protein, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and phosphorylated p38 mitogen-activated protein kinase (p38 MAPK) in the SG compared to MI rats. NONRATT021972 siRNA treatment prevented the pathophysiologic processes mediated by P2X7 receptors in the SG after myocardial ischemic injury.


Subject(s)
Myocardial Ischemia/genetics , Myocardial Ischemia/metabolism , RNA, Long Noncoding/genetics , Receptors, Purinergic P2X7/genetics , Receptors, Purinergic P2X7/metabolism , Stellate Ganglion/metabolism , Animals , Cytokines/biosynthesis , Immunohistochemistry , Myocardial Ischemia/enzymology , Myocardium/enzymology , Purinergic P2X Receptor Antagonists/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Small Interfering , Rats , Rats, Sprague-Dawley
5.
Purinergic Signal ; 12(1): 139-48, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26686228

ABSTRACT

Some long non-coding RNAs (lncRNAs) participate in physiological processes that maintain cellular and tissue homeostasis, and thus, the dysregulated expression of lncRNAs is involved in the onset and progression of many pathological conditions. Research has indicated that the genetic knockout of some lncRNAs in mice resulted in peri- or postnatal lethality or developmental defects. Diabetes mellitus (DM) is a major cause of peripheral neuropathy. Our studies showed that the expression levels of lncRNA uc.48+ in the diabetic rat dorsal root ganglia (DRG) and the DM patients' serum samples were increased. It suggested that lncRNA uc.48+ was involved in the pathophysiological process of DM. The aim of this study was to investigate the effects of lncRNA uc.48+ small interfering RNA (siRNA) on diabetic neuropathic pain (DNP) mediated by the P2X3 receptor in the DRG. The values of the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were measured by the von Frey test and Hargreaves' test, respectively. The levels of P2X3 protein and messenger RNA (mRNA) in the DRG were detected by reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry, and western blotting. The experiments showed that the MWT and TWL values in DM rats were lower than those in the control rats. The MWT and TWL values in DM rats treated with lncRNA uc.48+ siRNA were increased compared to those in DM rats, but there was no significant difference between the DM rat group and the DM + scramble siRNA group. The levels of P2X3 protein and mRNA in the DM DRG were higher than those in the control, while the levels of P2X3 protein and mRNA in the DG of DM rats treated with uc.48+ siRNA were significantly decreased compared to those in DM rats. The expression levels of TNF-α in the DRG of DM rats treated with uc.48+ siRNA were significantly decreased compared to those in the DM group. The phosphorylation and activation of ERK1/2 in the DM DRG were decreased by uc.48+ siRNA treatment. Therefore, uc.48+ siRNA treatment may alleviate the DNP by inhibiting the excitatory transmission mediated by the P2X3 receptor in DRG.


Subject(s)
Diabetic Neuropathies/genetics , Diabetic Neuropathies/physiopathology , Ganglia, Spinal/physiopathology , Neuralgia/genetics , Neuralgia/physiopathology , RNA, Long Noncoding/genetics , Receptors, Purinergic P2X3/genetics , Receptors, Purinergic P2X3/metabolism , Animals , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/metabolism , Diabetic Neuropathies/blood , Humans , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/genetics , Male , Pain Measurement , Phosphorylation , RNA, Small Interfering , Rats , Rats, Sprague-Dawley , Receptors, Purinergic P2X3/blood , Synaptic Transmission
6.
Int Immunopharmacol ; 28(2): 1044-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26344431

ABSTRACT

Evodiamine has been reported to exhibit anti-inflammatory and anti-nociceptive effects, but the underlying mechanisms remain to be defined. P2X4 receptor (P2X4R) is a subtype of ATP receptors and plays important roles in pain, inflammatory and immune responses. We aimed to investigate whether evodiamine has beneficial effects on endothelial inflammatory injury mediated by chronic high glucose condition. We found that culturing human umbilical vein endothelial cells (HUVECs) with high glucose significantly increased the expression of P2X4 receptor in HUVECs, cytosolic Ca(2+) concentrations and intracellular reactive oxygen species (ROS) while decreasing nitric oxide (NO); these effects could be reversed by evodiamine. High glucose also significantly increased the expression of the pro-inflammatory activators (NF-κB) and TNFR-ɑ, which was accompanied by the elevation of P2X4R levels. Evodiamine was able to down-regulate the elevated NF-κB, TNFR-ɑ, P2X4R and ROS, and up-regulate the decreased NO. Thus the evodiamine may exert the anti-inflammation activity on high-glucose challenge HUVEC via suppressing the P2X4R signaling pathway, exhibiting beneficial ability to protect HUVECs from glucotoxicity.


Subject(s)
Endothelium, Vascular/drug effects , Evodia , Inflammation/drug therapy , Quinazolines/pharmacology , Receptors, Purinergic P2X4/metabolism , Drugs, Chinese Herbal , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Glucose/metabolism , Human Umbilical Vein Endothelial Cells , Humans , NF-kappa B/metabolism , Nitric Oxide/metabolism , Reactive Oxygen Species/metabolism , Receptors, Purinergic P2X4/genetics , Receptors, Tumor Necrosis Factor/metabolism , Umbilical Veins/pathology , Up-Regulation/drug effects
7.
Purinergic Signal ; 11(2): 161-9, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25527178

ABSTRACT

Irritable bowel syndrome (IBS) and inflammatory bowel disease often display visceral hypersensitivity. Visceral nociceptors after inflammatory stimulation generate afferent nerve impulses through dorsal root ganglia (DRG) transmitting to the central nervous system. ATP and its activated-purinergic 2X7 (P2X7) receptor play an important role in the transmission of nociceptive signal. Purinergic signaling is involved in the sensory transmission of visceral pain. Moxibustion is a therapy applying ignited mugwort directly or indirectly at acupuncture points or other specific parts of the body to treat diseases. Heat-sensitive acupoints are the corresponding points extremely sensitive to moxa heat in disease conditions. In this study, we aimed to investigate the relationship between the analgesic effect of moxibustion on a heat-sensitive acupoint "Dachangshu" and the expression levels of P2X7 receptor in rat DRG after chronic inflammatory stimulation of colorectal distension. Heat-sensitive moxibustion at Dachangshu acupoint inhibited the nociceptive signal transmission by decreasing the upregulated expression levels of P2X7 mRNA and protein in DRG induced by visceral pain, and reversed the abnormal expression of glial fibrillary acidic protein (GFAP, a marker of satellite glial cells) in DRG. Consequently, abdominal withdrawal reflex (AWR) score in a visceral pain model was reduced, and the pain threshold was elevated. Therefore, heat-sensitive moxibustion at Dachangshu acupoint can produce a therapeutic effect on IBS via inhibiting the nociceptive transmission mediated by upregulated P2X7 receptor.


Subject(s)
Ganglia, Spinal/metabolism , Hyperalgesia/metabolism , Moxibustion , Receptors, Purinergic P2X7/metabolism , Animals , Disease Models, Animal , Irritable Bowel Syndrome/metabolism , Male , Moxibustion/methods , Rats, Sprague-Dawley
8.
Auton Neurosci ; 185: 36-42, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24746144

ABSTRACT

Adenosine triphosphate (ATP) plays an important role in signal transmission via acting on P2X receptors. P2X7 receptor is involved in pathophysiological changes of ischemic diseases. The PC12 cell line is a popular model system to study sympathetic neuronal function. In this study, the effects of P2X7 on the viability or [Ca(2+)]i in PC12 cells after exposure to oxygen-glucose deprivation (OGD) were investigated. The results showed that the viability of PC12 cells was decreased under the condition of OGD. BzATP, a P2X7 agonist, decreased the viability, while P2X7 antagonist oxATP or P2X7 siRNA reversed the viability of PC12 cells under the condition of OGD. The expression levels of P2X7 mRNA and protein in PC12 cells were up-regulated under the condition of OGD or BzATP treatment. The expression levels of P2X7 mRNA and protein were significantly decreased in OGD PC12 cells, which were pretreated with oxATP or P2X7 siRNA. It was also found that oxATP or P2X7 siRNA effectively suppressed the increase of [Ca(2+)]i induced by OGD. P2X7 agonist ATP or BzATP enhanced the [Ca(2+)]i rise induced by OGD in PC12 cells. The [Ca(2+)]i peak induced by ATP or BzATP in OGD group was decreased by ERK inhibitor U0126. Therefore, P2X7 antagonists or P2X7 siRNA could depress the sympathetic neuronal damage induced by ischemia.


Subject(s)
Adenosine Triphosphate/metabolism , Cell Hypoxia/physiology , Cell Survival/physiology , Glucose/deficiency , Receptors, Purinergic P2X7/metabolism , Animals , Blotting, Western , Butadienes/pharmacology , Calcium/metabolism , Enzyme Inhibitors/pharmacology , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Extracellular Signal-Regulated MAP Kinases/metabolism , Nitriles/pharmacology , PC12 Cells , Purinergic P2X Receptor Agonists/pharmacology , Purinergic P2X Receptor Antagonists/pharmacology , RNA, Messenger/metabolism , RNA, Small Interfering , Rats , Receptors, Purinergic P2X7/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...